| Description | Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist,is an antiparkinsonian agent. |
| In vitro | The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity[1]. |
| molecular weight | 293.45 |
| Molecular formula | C21H27N |
| CAS | 57982-78-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 2.93 mg/mL (10 mM) |
| References | 1. Eltze M.Multiple mechanisms of action: the pharmacological profile of budipine.J Neural Transm Suppl. 1999;56:83-105. 2. Parsons C G , Hartmann S , Spielmanns P . Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist: Patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones[J]. Neuropharmacology, 1998, 37(6):719-727. |